BR112012026289A2 - composto orgânico para uso no tratamento de câncer do fígado - Google Patents

composto orgânico para uso no tratamento de câncer do fígado

Info

Publication number
BR112012026289A2
BR112012026289A2 BR112012026289A BR112012026289A BR112012026289A2 BR 112012026289 A2 BR112012026289 A2 BR 112012026289A2 BR 112012026289 A BR112012026289 A BR 112012026289A BR 112012026289 A BR112012026289 A BR 112012026289A BR 112012026289 A2 BR112012026289 A2 BR 112012026289A2
Authority
BR
Brazil
Prior art keywords
liver cancer
organic compound
treating liver
treating
fluoro3
Prior art date
Application number
BR112012026289A
Other languages
English (en)
Inventor
Diana Graus-Porta
Hebert Schmid
Michael Shi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112012026289A2 publication Critical patent/BR112012026289A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composto orgânico para uso no tratamento de câncer do fígado. o uso de 4-amino-5-fluoro3-3[6-(4-metilpiperazin-1il)-1h-benzimidazil-2-il]-1h-quinolin-2-ona ou um sal ou um seu tautômero, ou um hidrato ou um solvato farmaceuticamente aceitável para a fabricação de composições farmacêuticas para uso no tratamento de carcionoma hepaticelular ou câncer do fígado.
BR112012026289A 2010-04-16 2011-04-14 composto orgânico para uso no tratamento de câncer do fígado BR112012026289A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32493610P 2010-04-16 2010-04-16
PCT/EP2011/055906 WO2011128403A1 (en) 2010-04-16 2011-04-14 Organic compound for use in the treatment of liver cancer

Publications (1)

Publication Number Publication Date
BR112012026289A2 true BR112012026289A2 (pt) 2016-07-12

Family

ID=44260208

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026289A BR112012026289A2 (pt) 2010-04-16 2011-04-14 composto orgânico para uso no tratamento de câncer do fígado

Country Status (17)

Country Link
US (1) US8741903B2 (pt)
EP (1) EP2558095B1 (pt)
JP (1) JP2013525291A (pt)
KR (1) KR20130073873A (pt)
CN (1) CN102844031A (pt)
AU (1) AU2011239999B2 (pt)
BR (1) BR112012026289A2 (pt)
CA (1) CA2793779A1 (pt)
DK (1) DK2558095T3 (pt)
ES (1) ES2707625T3 (pt)
HU (1) HUE042535T2 (pt)
MX (1) MX2012012051A (pt)
PL (1) PL2558095T3 (pt)
PT (1) PT2558095T (pt)
RU (1) RU2012148710A (pt)
TR (1) TR201819653T4 (pt)
WO (1) WO2011128403A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN105611980A (zh) * 2014-03-17 2016-05-25 英丘伦有限责任公司 治疗肝癌的组合物和方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174632A1 (en) 2000-09-11 2011-10-28 Novartis Vaccines & Diagnostic Quinolinone derivatives
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
BRPI0507891A (pt) * 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
EP2301546B1 (en) * 2005-01-27 2014-09-10 Novartis AG Treatment of metastasized tumors
CN101146538A (zh) * 2005-01-27 2008-03-19 诺华疫苗和诊断公司 转移瘤的治疗
RU2425041C2 (ru) 2005-05-23 2011-07-27 Новартис Аг Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona

Also Published As

Publication number Publication date
PL2558095T3 (pl) 2019-06-28
US8741903B2 (en) 2014-06-03
KR20130073873A (ko) 2013-07-03
CA2793779A1 (en) 2011-10-20
AU2011239999B2 (en) 2014-04-03
CN102844031A (zh) 2012-12-26
JP2013525291A (ja) 2013-06-20
EP2558095A1 (en) 2013-02-20
DK2558095T3 (en) 2019-01-14
US20130123272A1 (en) 2013-05-16
ES2707625T3 (es) 2019-04-04
TR201819653T4 (tr) 2019-01-21
MX2012012051A (es) 2012-11-22
HUE042535T2 (hu) 2019-07-29
EP2558095B1 (en) 2018-10-24
PT2558095T (pt) 2019-01-29
AU2011239999A1 (en) 2012-11-08
RU2012148710A (ru) 2014-05-27
WO2011128403A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
BR112012026289A2 (pt) composto orgânico para uso no tratamento de câncer do fígado
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
BR112016011949A8 (pt) composto, composição farmacêutica, e, uso dos mesmos”
PH12016500024A1 (en) Bromodomain inhibitor
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
MX2015011504A (es) Inhibidores de ras y sus usos.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
BR112013000651A2 (pt) combinações de inibidores de cinase para o tratamento de câncer.
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
WO2012155066A3 (en) Spiro-oxindole mdm2 antagonists
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
PH12015501088A1 (en) Dimeric compounds
WO2013040227A3 (en) Therapeutic compounds
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]